DEPARTMENT OF PHARMACEUTICALS
(Ministry of Chemical & Fertilizers Government of India)

PROJECTS & DEVELOPMENT INDIA LIMITED
(A Govt. of India Undertaking)

पी डी आई एल
PDIL

Government of India
Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers

Call dated 23-11-2016
for
Expression of Interest (EOI) – 4th Phase
For
Participation in Cluster Development Programme for Pharma Sector

Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India, intends to facilitate establishing/ upgrading of the Common Facility Centers under Cluster Development Programme for Pharma Sector, in Public Private Partnership (PPP) mode. DoP has engaged **Projects & Development India Ltd. (PDIL),** a Public Sector Undertaking, under Ministry of Chemicals& Fertilizers, Govt. of India, as Project Management Consultant (PMC) for this programme.

For this purpose, PDIL on behalf of **DoP invites the EOI from Special Purpose Vehicle (SPV) : A non-profit making company registered either under Section 25 of the Companies Act, 1956 or under Section 8 of new Companies Act,2013, to participate in the Cluster Development Programme**, which aims for setting up of new Common Facility Centers as well as up gradation of existing Common Facilities, which could catalyze and encourage quality, productivity and innovation in Indian Pharma Sector.

The scheme would be implemented in Public Private Partnership (PPP) mode through one time grant-in-aid, to be released for creation of identified infrastructure and common facilities to a Special Purpose Vehicle (SPV).

The prime motive behind this Programme is to benefit the Small & Medium Pharma Units/Enterprises by grant-in-aid (70 % of Project Cost, subject to Max. Rs. 20.0 Crore) for Installation/Upgradation of the Common Facility Centers to boost up their competitiveness and capability in the Global Market

DK Saraf
23/11/2016

DEPARTMENT OF PHARMACEUTICALS

(Ministry of Chemical & Fertilizers Government of India)

PROJECTS & DEVELOPMENT INDIA LIMITED

(A Govt. of India Undertaking)

पी डी आई एल
PDIL

The following type of Special Purpose Vehicles (SPVs) may participate in this Programme:-

(1) SPVs comprising of Private Pharma Units and/or Govt. Pharma Units
(2) SPVs comprising of Private Pharma Units and/or Govt. Pharma Units, lead by a Govt. Organisation/PSU (Pharma or Non-Pharma).

Interested ***representatives of*** **Special Purpose Vehicles (SPVs)**, meeting the prescribed criteria herein are hereby invited to submit their "**Expression of Interest" (EOI) for Participation in Cluster Development Programme; on or before 15-12-2016 (03:00 PM),** as per prescribed proforma at the following address:-

Mr. P.K. Singh,
GM (Civil),
Projects & Development India Limited,
PDIL, Bhawan,
A-14, Sector-1,
Noida, U.P. 201301
Phone : 0120-2529833.
Email : pksingh@pdilin.com

For electronic communication, please address your emails to Mr. P.K. Singh, GM (Civil), pksingh@pdilin.com with copy marked to Mr. D.K. Sant, DGM (Projects), dksant@pdilin.com

For complete details of the scheme, please visit following websites:-
http://pharmaceuticals.gov.in and pdilin.com

It is requested to visit the above websites time to time for updations about this scheme.

EOI documents- Incomplete or received after due date- will stand rejected without any reference to the applicants.

D K Sant
23/11/2016

DEPARTMENT OF PHARMACEUTICALS
(Ministry of Chemical & Fertilizers Government of India)

PROJECTS & DEVELOPMENT INDIA LIMITED
(A Govt. of India Undertaking)

पी डी आई एल
PDIL

Department of Pharmaceuticals,
Ministry of Chemicals & Fertilizers
Government of India

EXPRESSION OF INTEREST (EOI)

For

Participation in Cluster Development Programme for Pharma Sector

For
Establishing/ upgrading the Common Facility Centers under Cluster Development Programme for Pharma Sector, in Public Private Partnership (PPP) mode.

DKSaxena
23/11/2016

CONTENTS

DRSaxena
23/11/2016

DISCLAIMER

- Department of Pharmaceuticals (DoP)/ Projects & Development India Ltd. (PDIL) have prepared this document to give interested parties background information on the Programme/Scheme. While Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers/ PDIL have taken due care in the preparation of the information contained herein and believe it to be accurate, neither Ministry of Chemicals & Fertilizers, Government of India nor Department of Pharmaceuticals of the Government of India, any of its authorities or agencies or any of their respective officers, employees, agents or advisors gives any warranty or make any representations, express or implied as to the completeness or accuracy of the information contained in this document or any information which may be provided in association with it.

- The information is not intended to be exhaustive. Interested parties are required to make their own inquiries before taking decision to submit their Expression of Interest. The information is provided on the basis that it is non-binding on Ministry of Chemicals & Fertilizers, Government of India or the Department of Pharmaceuticals, any of its authorities or agencies or any of their respective officers, employees, agents or advisors.

- Ministry of Chemicals & Fertilizers, Government of India reserves the right not to proceed with the Project or to change the configuration of the Project, to extend the time table reflected in this document or to change the process or procedure to be applied. It also reserves the right to decline to discuss the matter further with any party expressing interest.

- No reimbursement of cost of any type will be paid to persons or entities expressing interest in response to this document.

****

DRSaraf
23/11/2016

DEPARTMENT OF PHARMACEUTICALS
(Ministry of Chemical & Fertilizers Government of India)

PROJECTS & DEVELOPMENT INDIA LIMITED
(A Govt. of India Undertaking)

पी डी आई एल
PDIL

SCHEDULE FOR THE SUBMISSION OF Expression of Interest (EOI) – 4th Phase

For

Participation in Cluster Development Programme for Pharma Sector

Sl. No.	Particulars	DATE
1.0	Date of availability of EOI documents on DoP & PDIL website	23-11-2016
2.0	Last date for receiving queries	30-11-2016
3.0	Time and Date of Pre- Application conference at PDIL Noida	01-12-2016 (11AM)
4.0	Date of issue of Corrigendum/Addendum, if any	05-12-2016
5.0	Application Due Date / EOI Submission Date	15-12-2016 (03:00 PM)

DKSaxena
23/11/2016

DEFINITIONS:-

Until otherwise stated so, the following terms & expressions used in this document would have following meanings:

"EOI" means Expression of Interest.

"RFP" means Request for Proposals.

"Applicant" means **duly authorized representatives of Special Purpose Vehicle (SPV) : A non-profit making company registered either under Section 25 of the Companies Act, 1956 or under Section 8 of new Companies Act,2013,** and having requisite experience and who have downloaded the EOI document from the website of Department of Pharmaceuticals or from website of Projects & Development India Ltd. in the Ministry of Chemicals & Fertilizers for participation in the CDP-Pharma Sector.

"Application" means the EOI submitted by an Applicant interested in the Scheme, in the prescribed format.

"DoP" means Department of Pharmaceuticals in the Ministry of Chemicals & Fertilizers, Government of India, who have invited the Applications for EOI.

"PMC" means Project Management Consultant, engaged by DoP for implementation of this Programme/scheme.

"SME" means Small & Medium Enterprises.

"MSME" means Medium, Small & Micro Enterprises.

"SPV" means Special Purpose Vehicle :- A non-profit making company registered either under Section 25 of the Companies Act, 1956 or under Section 8 of new Companies Act,2013. It will have the representatives from cluster members, financial institutions, State Government and R&D organization. The SPV shall have full operational autonomy to develop, operate and maintain the CFC.

"CFC" means Common Facility Centers/ Common Assets; such as common test center, training center, R&D center, Effluent Treatment Plant, common logistics center and any other technically justified facility, as per requirement of the cluster members.

A K Sanyal
23/11/2016

"DPR" means Detailed Project Report for common facilities to be developed for a cluster.

"CDP-PS" means Cluster Development Programme for Pharma Sector.

"SSC" means Scheme Steering Committee.

DKSanyal
23/11/2016

SECTION –I

EXPRESSION OF INTEREST (EOI)

For

Participation in Cluster Development Programme for Pharma Sector

For
Establishing/ upgrading the Common Facility Centers under Cluster Development Programme for Pharma Sector, in Public Private Partnership (PPP) mode.

GENERAL INFORMATION OF PROGRAMME/SCHEME

&

INSTRUCTIONS TO APPLICANTS

DK Sanyal
23/11/2016

1.0 INSTRUCTIONS TO APPLICANTS

1.1 INTRODUCTION & PROJECT EXECUTION PLAN

1.1.1 Introduction

a) The DoP intends to facilitate establishing/ upgrading the Common Facility Centers under Cluster Development Programme for Pharma Sector, in Public Private Partnership (PPP) mode through a PMC.
b) The proposed cluster to be developed or upgraded under the Scheme have to comply with international norms as well as guidelines laid down by DoP, GOI
c) For this purpose it is proposed to select the SPVs.

1.1.2 Project Execution Plan:-

a) Engagement of PMC by DoP for scheme realization:- DoP has already engaged PDIL as PMC.
b) Selection of SPVs for Clusters :- PMC shall assist DoP in selection of SPVs, based on the EOIs received from the SPVs, for clusters in different parts of India, in which CFCs are to be developed / upgraded. The role and functions of SPV are given in next pages.
c) The selected SPVs shall be requested to submit their proposals alongwith DPR, as per DoP/PMC format (which shall be sent to selected SPVs), for the proposed CFC (Common Facility Centre) for their cluster e.g. Common testing facilities, training centers, R&D Centers, ETP, Common Logistics Centre, etc.
d) PMC shall review the Proposals & DPR and then SSC shall approve the project components (DPR) and funding depending on the merits of the proposal. After approval of Proposal/DPR, the SPV shall prepare Tender Documents under guidance of DoP/PMC, for award of execution job to a suitable Executing Agency/Contractor on Lumpsum Turnkey (LSTK) basis. The grant shall be released in parts, based on the progress of work.
e) The land for CFC shall be arranged by SPV / Stakeholders.
f) The maximum limit for grant-in-aid per cluster for CFC shall be Rs. 20.0 Crore or 70% of the cost, whichever is less. This includes cost of Land also. The contribution of the SPV shall be at least 10% of the overall project cost. Rest of the amount will be arranged through State Govt. or contribution/equity by SPV/Stakeholders or through loan by the SPV.

For example:-
If the Cost of CFC is Rs. 30 Crores. Then, the grant shall be Rs. 20.0 Crores. SPV shall have to contribute atleast 10% (i.e. Rs. 3.0 Crores). Rest amount of Rs. 7.0 Crores shall be arranged through State Govt. or contribution by SPV/Stakeholders or through loan from Banks by SPV.

1.2 ROLE & FUNCTIONS OF PROPOSED SPECIAL PURPOSE VEHICLE (SPV)

The role and functions of the SPV shall include, but not limited to the following:-

i. The project shall be implemented through a Special Purpose Vehicle (SPV). It shall have the representatives from cluster members, financial institutions, State Government and R&D organization. The SPV shall have full operational autonomy to develop, operate and maintain the infrastructure.

D K Sanyal
23/11/2016

ii. SPV should represent the cluster as a whole and shall have a minimum of 10 manufacturer enterprises of pharma producers as its shareholders.

iii. The share of the cluster beneficiaries should be as high as possible, but not less than 10 per cent of the total cost of CFC. State Government's / other stakeholder's contribution will be considered as gap filling funds. All the participating units should be independent in terms of their financial stakes and management. No single unit will hold more than 10 per cent in the equity capital (or equivalent capital contribution) of the SPV.

iv. Large mother manufacturing firms (whether in the public or private sector), other major buyers of the cluster MSE products, commercial machinery suppliers, raw material suppliers and business development service (BDS) providers can also be members of SPV, provided management of SPV remains clearly with the intended beneficiary SPV. The SPV may also raise loans from banks to take care of any shortfall, expansion, etc. on the condition that the plant and machinery in the CFC purchased with Government assistance will not be hypothecated and the first right thereto will rest with the Government.

v. Pharma enterprises shall hold at least 51% equity of the SPV and remaining may be held by any Government agency, Financial Institution / Bank, strategic partners etc.

vi. The shareholding / member enterprises taking / holding stake in the SPV shall be legally independent entities without any related party relationship with each other as described under Accounting Standard (AS) 18 of the Companies (Accounting Standard) Rules, 2006.

vii. No dividends to be declared by the SPV-rather the profits to be ploughed back into the SPV and the accounts of SPV shall be subject to audit by Comptroller & Auditor General of India.

viii. The SPV will have quarterly meetings and will prepare Annual Report.

ix. Although SPV/Project Implementing Agency would fulfill the requirements as decided by SSC to avoid any conflict of interest and smooth implementation and operation of the project, however the board activities and roles played by SPV would be the following:-

   a. Prepare the Detailed Project Report covering the technical, financial, institutional and O&M aspects of the projects
   b. Raise balance amount of Project cost.
   c. Obtaining any statutory approval / clearances including release of funds.
   d. Recruit suitable functional professionals in order to ensure that the project is executed smoothly.
   e. Implement various interventions as outlined and approved in DPR.
   f. O&M of assets created under the project by way of user services.
   g. Furnish regular progress reports to DoP/PDIL.

1.3 TIME SCHEDULE FOR THE SCHEME

The time frame for implementation of an approved project would be 2 years from the date of approval of the project/proposal.

1.4 ELIGIBILITY CRITERIA FOR SELECTION OF SPECIAL PURPOSE VEHICLE (SPV)

1) The SPV member should be a Drug Manufacturer/ Pharma Enterprise, Drug Intermediate Manufacturer, State Govt. and Pharma R&D Organization. However, major Buyer of the Cluster Products, Commercial Machinery Suppliers, Raw material Suppliers and Business Development Service can also be members of SPV, provided management of SPV remains clearly with the intended beneficiary SPV.

DR Sanyal
23/11/2016

2) The SPV should have identified land of adequate size for the proposed CFC.
3) The cluster member should be located within radius of about 15 kms from the proposed CFC.
4) The cluster member should have not been blacklisted by the central Government / any state government or under a declaration of ineligibility for corrupt or fraudulent practices as on the last date of submission of response to EoI. In this regard, a declaration to be submitted by all the members of SPV.
5) SPV shall have a minimum of 10 manufacturer enterprises of pharma producers as its shareholders.

Note :- SPVs lead by a Govt. Organisation/PSU (Pharma or Non Pharma) will also be considered.

It may also be noted that the EOIs meeting the eligibility criteria shall be shortlisted for issuance of Request for Proposal (RFP) to SPVs for submission of Proposal alongwith DPR to DoP/PDIL. The RFP shall contain the Evaluation Criteria for evaluation of Proposals/DPRs.

1.5 INSTRUCTION FOR FILLING UP THE APPLICATION FORMS/EOI FORMS:

1.5.1 All the information called for in the forms provided in Section II should be furnished against the relevant columns in the forms. If for any reason, information is furnished on a separate sheet, this fact should be mentioned against the relevant column. Even if no information is to be provided in a column, a 'nil' or 'no such case' entry should be made in that column. If any particulars/ query is not applicable in case of the applicant, it should be stated as 'not applicable'.

1.5.2 The applicants are cautioned that not giving complete information called for in the application forms or not giving it in clear terms or making any change in the prescribed forms or deliberately suppressing the information may result in the applicant being summarily disqualified.

1.5.3 The EOI should be type-written in English Language only.

1.5.4 The applicant may furnish any additional information, which is deemed necessary to establish their capability to successfully complete the envisaged project. Superfluous information need not be furnished and no information shall be entertained after submission of EOI document unless specifically called for.

1.5.5 Any information furnished by the applicant found to be incorrect either immediately or at a later date, would render the firm liable to be debarred from participation in the scheme.

1.5.6 EOI sent by Email or Fax or incomplete applications or received after last date of receipt of application shall not be entertained.

1.5.7 The applicant should submit a checklist as per the attached Form along with Application indicating necessary attachments.

1.6 Processing Fee

1.6.1 Processing Fee of Rs. 10,000/- shall be paid by SPV while submission of EOI, in the form of DD in favour of Projects & Development India Ltd., payable at Noida. This Fee shall be Non-refundable. The Applications without Processing Fee shall not be considered.

1.6.2 The Applicant shall bear all costs associated with the preparation and submission of its application. The Department of Pharmaceuticals will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the EOI/pre-qualification process.

DRSaraf
23/11/2016

1.7 SIGNING OF THE APPLICATION AND NUMBER OF COPIES:

1.7.1 The Applicant (i.e. representative of Association of Firms) shall prepare one original set of the EOI documents and clearly mark them "ORIGINAL". The original of the Application shall be signed on all the pages by the person duly authorized to sign on behalf of the Association of Firms. The power of attorney duly notarized and on a stamp paper authorizing the person to sign and act on behalf of the Association of Firms, should be submitted.

1.7.2 The Applicant shall submit two signed hard copies of Original Application and clearly mark them "COPY". In the event of any discrepancy between the original and the copies, the original shall prevail. A soft copy of the Application may also be provided on a CDROM alongwith the Application.

1.7.3 An authorized representative shall have the authority to conduct all business and incur liabilities related thereto for and on behalf of the Association of Firms, during the short-listing process and thereafter.

1.8 SEALING OF APPLICATION

The Original alongwith DD & the copies of Application enclosed in separate envelopes shall be sealed in a large envelope and submitted on or before date, prescribed for submission of the Application as specified in Schedule of submission of EOI

1.9 DEADLINE AND ADDRESS FOR SUBMISSION OF APPLICATIONS

1.9.1 Applications shall be submitted to the address given in Schedule of submission of EOI, by hand or through registered post or courier service on or before date, prescribed for submission of the Application as specified in Schedule of submission of EOI.

1.9.2 DoP/PDIL shall not assume any responsibility for any delayed delivery and such applications received after due date, will not be entertained.

1.9.3 The Application should be addressed to:

Mr. P.K. Singh,
GM (Civil),
Projects & Development India Limited,
PDIL, Bhawan,
A-14, Sector-1,
Noida, U.P. 201301
Phone : 0120-2529833.
Email : pksingh@pdilin.com

All envelopes shall be titled **"Submission of EOI (4th Phase) for participation in the Cluster Development Programme for Pharma Sector (CDP-PS)"** and clearly marked in English with typed name and address of the Applicant.

1.9.4 DoP/PDIL may, at its discretion, extend the deadline for the submission of Applications, in which case all rights and obligations of DoP/PDIL and the Applicants subject to the previous deadline shall thereafter be subject to the deadline as extended.

AKSaxena
23/11/2016

1.10 LATE APPLICATIONS

Application received after the deadline of submission of Application will not be considered or opened under any circumstances.

1.11 CLARIFICATIONS

1.11.1 The Applicants shall be evaluated on the basis of the Contents of the Application and the supporting documents submitted by them. DoP/PDIL shall not be under any obligation to seek any further information or clarifications.

1.11.2 Without prejudice to Clause 1.11.1 above, in order to assist in the evaluation of Applications, DoP/PDIL may, at its sole discretion, ask any Applicant for any clarification on its Application which shall be submitted within a stated reasonable period of time. Any request for clarification and all clarifications shall be in writing.

1.11.3 If an Applicant does not provide clarifications requested by the date and time set in DoP's /PDIL request for clarification, its Application is liable to be rejected.

1.11.4 It is clarified that Applicants shall not be required to submit on their own, additional information or material subsequent to the date of submission and such material if submitted shall be disregarded. It is therefore essential to ensure that all questions are answered fully on the proforma or otherwise. All the pages of the EOI document and Annexures and additional information if any submitted shall be numbered sequentially and signed and stamped. General responses such as "included in brochure" without specific item reference may be avoided.

1.12 RESPONSIVENESS OF APPLICANTS

1.12.1 An application, which does not meet all the requirements of the EOI document, may be rejected.

1.12.2 Applicants should note that this EOI document and Questionnaire is intended to provide preliminary information. The information contained herein shall not in any way be construed as binding on DoP/PDIL, its agents, successors or assignees.

1.12.3 The suitability of any member of SPV may be reviewed by DoP/PDIL.

1.12.4 All the documents and other information submitted by an Applicant to DoP/PDIL shall become the property of Department of Pharmaceuticals. Applicants are to treat all information as strictly confidential. DoP/PDIL will not return any EOI document submitted to it by the Applicants.

1.12.5 DoP/PDIL shall notify successful Applicants after evaluation. It will not entertain any query or clarification from Applicant(s) who are not short listed in the EOI process.

1.13 WITHDRAWAL OF APPLICATIONS

1.13.1 No modification or substitution of the submitted application shall be allowed.

1.13.2 An Applicant may withdraw its Application after submission, provided that written notice of the withdrawal is received by DoP/PDIL before the last date for submission of Applications. In case an applicant wants to resubmit his application, he shall submit a fresh application following all the applicable conditions.

1.13.3 The withdrawal notice shall be prepared in Original only and each page of the notice shall be signed and stamped by authorized signatory. The copy of the notice shall be duly marked "WITHDRAWAL".

DKSaxena
23/11/2016

1.14 RIGHT TO ACCEPT/REJECT ANY OR ALL APPLICATIONS

The DoP/PDIL reserves the right to accept or reject any or all Applications and to annul the qualification process at any time without any liability or any obligation for such acceptance, rejection or annulment, without assigning any reasons.

1.15 ATTACHMENTS

1.15.1 Applicants should attach clearly marked and referenced continuation sheets in the event that the space provided in the EOI Document, Questionnaire or Annexure is in-sufficient.

1.15.2 While responding to the EOI advertisement the Applicants should attach the necessary documents/certificates, as asked in the EOI document/advertisement.

1.15.2 It is expressly clarified that before submitting the EOI, Applicant must have examined carefully the contents of all the attached documents and any failure to comply with any of the requirement of EOI document will be at the Applicant's risk.

1.16 VALIDITY OF APPLICATIONS

1.16.1 Application shall be valid for a period of 180 days from the last date of submission of Applications after which the Department may choose to destroy these application in a manner deemed fit by it.

1.16.2 The DoP/PDIL retains the right that in exceptional circumstances at its own discretion, it may ask the applicants to extend the validity of their application for a specified period. The Applicant not submitting the letter of extension of the validity period at that time shall not be further considered.

1.17 JURISDICTION

All disputes arising shall be subject to the jurisdiction of the appropriate court at **Delhi** and will be governed by the laws of India.

DKSaini
23/11/2016

SECTION –II

EXPRESSION OF INTEREST (EOI)

For

Participation in Cluster Development Programme for Pharma Sector

For

Establishing/ upgrading the Common Facility Centers under Cluster Development Programme for Pharma Sector, in Public Private Partnership (PPP) mode.

PROFORMA APPLICATION FORMS

DRS Ayogi
23/11/2016

LETTER OF SUBMISSION OF EOI

Date :

To,

Mr. P.K. Singh,
GM (Civil),
Projects & Development India Limited,
PDIL, Bhawan,
A-14, Sector-1,
Noida, U.P. 201301
Phone : 0120-2529833.
Email : pksingh@pdilin.com

SUBJECT:EOI (4th Phase) for Participation in Cluster Development Programme for Pharma Sector
Location/Address of the Cluster / SPV :.....

Dear Sir,

Having gone through the details given in EOI Notice dated 23-11-2016 and EOI document for the above project, I on behalf of my SPV (details mentioned in the attached documents) hereby submit the relevant information for considering my/our EOI.

1. I / We agree to abide by all the instructions, terms and conditions mentioned in the EOI document.
2. I/ We hereby confirm that we have already formed SPV, as per EOI Notice. The signed & stamped copy of documentary proof about formation of SPV is also attached with this EOI.
3. I / We hereby confirm that in our SPV, members from Pharma Industry are 10 or more. The details are given in the annexures/attached documents.
4. I / We hereby certify that all the statements made and information supplied in the enclosed Annexures and accompanying statements/documents are true and correct.
5. I/ We have furnished all information and details necessary for EOI and have no further pertinent information to supply.
6. I / We authorize Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India or their authorized representatives to approach individuals, employers and firms to verify our competence and general reputation.
7. I/We enclose in the prescribed formats certificates/documents, as required.
8. I/We shall be jointly and severally liable to DoP/PDIL for the successful Implementation of the Programme/Scheme.

23/11/2016

9. I/We hereby confirm that we have identified land for CFC.
10. I/ We hereby confirm that all the cluster member firms are within 15 km radius from location of proposed CFC.
11. I/We hereby confirm that none of the member firms of our SPV is blacklisted by Central Govt. / State Govt.
12. I/ We hereby confirm that the SPV members shall contribute atleast 10% of Total Project Cost as Equity
13. The details of Processing Fee are given below:-
    DD No. ..... Date..... Issuing Bank.....DD Amount.....

Date :

Signature & Seal of Authorized Representative of SPV
(Name of Authorized Representative of the SPV)
(Mobile No. of Authorized Representative of the SPV)

Enclosures:-

1	Details of Authorized Representative & Alternative Representative of SPV	Annexure-I
2	Details of the Members of SPV	Annexure-II
3	Authorization Letter for Representative & Alternative Representative of SPV	Annexure-III
4	General Information about Member Firms of SPV	Annexure-IV
5	Financial Status of the Cluster Member/Firms	Annexure-V
6	Requirement / Availability of Centralized / Common Facilities	Annexure-VI

DKSanyal
23/11/2016

Annexure - I

Details of Authorized Representative of SPV

Location/Address of the Cluster / SPV :.....

Name	
Company Name	
Address (O) Address (R)	
Mobile No. Landline No. Fax No. Email Address	

Date :

Signature & Seal of Authorized Representative of SPV
(Name & Mobile No. of Authorized Representative of the SPV)

Details of Authorized Alternative Representative of SPV

Name	
Company Name	
Address (O) Address (R)	
Mobile No. Landline No. Fax No. Email Address	

Date :

Signature & Seal of Authorized Alternative Representative of SPV
(Name & Mobile No. of Authorized Alternative Representative of the SPV)

DRSaxt
23/11/2016

Annexure- II

DETAILS OF THE MEMBERS OF SPV
(To be filled by the Representative of SPV)

Location/Address of the Cluster / SPV :.....

Sl. No.	Name of SPV Member	Address of firm/member	Name, Email ID and Mobile No. of member	Remarks
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				

Date :

Signature & Seal of Authorized Representative of SPV

Note:- Attach separate sheets, if required.

DK Sanyal
23/11/2016

Annexure- III

AUTHORIZATION LETTER FOR REPRESENTATIVE & ALTERNATIVE REPRESENTATIVE OF SPV

(To be submitted in the Letter Head of the individual member/firm and to be signed by its Authorised Signatory)

Location/Address of the Cluster / SPV :.....

I/We ..... Authorized Signatory of ....., which is a member of above mentioned SPV, hereby nominate Mr. .....S/o Mr. .....R/o ..... **as our representative and** Mr. .....S/o Mr. .....R/o ..... **as our alternative representative.**

I/We also authorize them to sign all the documents pertaining to this Programme/Scheme, on behalf of this SPV, for the successful implementation of "Cluster Development Programme for Pharma Sector",

Date : Signature & Seal of Authorized Signatory of Firm

23/11/2016

Annexure- IV

GENERAL INFORMATION ABOUT MEMBER FIRMS OF SPV
(To be filled by each member/firm of the SPV)

Location/Address of the Cluster / SPV :.....

1. Name of the representative of the Cluster Member/Firm ----------

2. Name of the Firm
   Address of Firm
   Legal Status of the Firm (Individual/Partnership/etc.)
   Tel. No. & Fax No.
   Website Address:

3. PAN and TIN of the Firm (Attach copy of document).
   .....
   .....
   .....

4. Contact Person, Designation and Address including e-mail id
   .....
   .....
   .....
   .....

5. Number of years in Pharma Industry.

6. **Achieved Quality Certification/ Plan for the Quality Certification in Future:**
   (Like as ISO, CE Mark any other special Technical Training)

SL. No.	Description/ Details	Certifying Agency	Year of Certification	Achieved / Ongoing certification	Remark / Future proposals
1					
2					
3					
4					

7. Has the applicant or any constituent partner in case of partnership firm, ever been debarred / black listed by Central/ State Government at any time for competing in any organization? If so, give details.

DKSaxena
23/11/2016

8. Has the applicant or any constituent partner in case of partnership firm, ever been convicted by any court of law? If so, give details.

Signature of the representative of the Member Cluster/Firm
(Name & Mobile No. of Representative of the Member Cluster/Firm)

Date :

Signature & Seal of Authorized Representative of SPV

23/11/2016

Annexure- V

FINANCIAL STATUS OF THE CLUSTER MEMBER/FIRM
(TO BE FURNISHED SEPARATLY BY EACH MEMBER/FIRM)

Location/Address of the Cluster / SPV :.....

Name of the representative of the Firm	
Company Name and Address	
Mobile No. Landline No. Fax No. Email Address	
Field of Business / Type of manufacturing unit (Formulation / bulk drugs)	

SL NO.	YEAR	2013 - 14	2014 – 15	2015 – 16
1	Total assets			
2	Current assets			
3	Total liabilities			
4	Profit before taxes			
5	Profit after taxes			
6	Net Worth			
7	Any other Financial Details			

Note:

1. The details furnished in Annexure-V must be certified by Chartered Accountant.
2. At the time of submission of DPR, historic financial statements corresponding to the accounting periods already completed and audited by Chartered Accountant must be submitted (no statements for partial periods will be accepted).

Signature of the representative of the Member Cluster/Firm

Date :

Signature & Seal of Authorized Representative of SPV

DRSangi
23/11/2016

Annexure- VI

Requirement / Availability of Common Facilities
(To be filled by Authorised Representative of SPV)

Location/Address of the Cluster / SPV :.....

Sl. No	Facility	Requirement	Available (Capacity)	Remarks
1.	Infrastructure like: a) Land (Sq. Mtrs.) b) Roads c) Power, d) Water e) Any other, please specify.			
2.	Effluent Treatment Plant			
3.	Raw material and product testing facility			
4.	Medical Facilities			
5.	Infrastructure requirement for Specialty like Analytical lab, Toxicology Centre, Product validation Laboratory, Raw material Testing, Standardizations Laboratory Incinerators & etc.			
6.	Any special requirement (in case of Speciality & Pharma Segments)*			

*Description to be made available.

Date :

Signature & Seal of Authorized Representative of SPV

DR Sanyt
23/11/2016

CHECK LIST OF DOCUMENTS, TO BE SUBMITTED WITH THE EOI

Location/Address of the Cluster / SPV :.....

Sl. No.	DETAILS	Submitted / Not Submitted	Remarks
1	Letter of Submission of EOI containing the details of Processing Fee		
2	Details of Authorized Representative & Alternative Representative of the SPV (Annexure-I)		
3	Details of the Members of SPV (Annexure-II)		
4	Authorization Letter for Representative & Alternative Representative of SPV (Annexure-III)		
5	General Information about Member Firms of SPV (Annexure-IV)		
6	Financial Status of the Cluster Member/Firms (Annexure-V)		
7	Requirement / Availability of Centralized / Common Facilities (Annexure-VI)		
8	Documents in support of Eligibility Criteria		
9	A set of complete EOI document, as downloaded from DoP/PDIL website, duly signed & stamped on each page by Representative of SPV, as a token of acceptance to the Terms & Conditions.		

Signature of the Authorized Alternative Representative of the proposed SPV

Date :

Signature & Seal of Authorized Representative of SPV

DR Sanyal
23/11/2016